Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432190 | 1.00 | CPS1 (0.43) | CPS1MEN1KMT2AHRH3DPP4 | |
| SCHEMBL1431705 | 0.88 | HRH3 (0.45) | MEN1KMT2AHRH3DPP4 | |
| SCHEMBL1431707 | 0.88 | HRH3 (0.45) | MEN1KMT2AHRH3DPP4 | |
| SCHEMBL1432116 | 0.83 | MEN1 (0.50) | CPS1MEN1KMT2AHRH3 | |
| SCHEMBL1432118 | 0.83 | MEN1 (0.50) | CPS1MEN1KMT2AHRH3 | |
| SCHEMBL1431922 | 0.83 | L3MBTL3 (0.48) | MEN1KMT2AHRH3DPP4 | |
| SCHEMBL1431921 | 0.83 | L3MBTL3 (0.48) | MEN1KMT2AHRH3DPP4 | |
| SCHEMBL1431606 | 0.81 | HRH3 (0.48) | CPS1MEN1KMT2AHRH3KCNH2 | |
| SCHEMBL1431608 | 0.81 | HRH3 (0.48) | CPS1MEN1KMT2AHRH3KCNH2 | |
| SCHEMBL1432198 | 0.81 | MEN1 (0.48) | CPS1MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524344-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110098300-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | US | claimed |
| EP-2300426-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2011-03-30 | — | — | EP | claimed |
| WO-2009147149-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-12-10 | — | — | WO | claimed |
| US-20110098300-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | US | disclosed |
| EP-2300426-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009147149-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098300-A1 | Compounds Comprising A Cyclobutoxy Group | CHAT, BACE1, GRIN2B | CPS1 2691/4885MEN1 4773/4885KMT2A 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.